See full press release   TORONTO, ONTARIO July 6, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming PSYCH Investor Summit: Research & Development. The conference will be held virtually on July 7, 2021. Braxia CEO Dr. Roger McIntyre will deliver a presentation discussing the recently announced funding by the Canadian Institutes Of Health Research (CIHR), of the Government of Canada, to support the first of its kind Ketamine clinical trial for Bipolar Depression. Additionally, Dr. McIntyre will discuss Braxia’s initiatives related to developing innovative therapeutics and delivery systems, while also administering patient care in its growing network of clinics. The presentation will be followed by a Q&A. Dr. McIntyre...